Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles M Beasley

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
Journal of Clinical Psychopharmacology|May 16, 2007
All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysisCharles M Beasley, Virginia L Stauffer, Hong Liu-Seifert, et al.
Journal of Clinical Psychopharmacology|November 16, 2007
Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trialsCharles M Beasley, Susan G Ball, Mary E Nilsson, et al.
Pacing and Clinical Electrophysiology : PACE|May 4, 2011
Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditionsCharles M Beasley, Charles Benson, Jessie Q Xia, et al.
The Journal of Clinical Endocrinology and Metabolism|June 7, 2002
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placeboMargaret O Sowell, Nitai Mukhopadhyay, Patrizia Cavazzoni, et al.
Pharmaceutical Research|May 23, 2006
Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysisWilliam J Crumb, Sean Ekins, R Dustan Sarazan, et al.
The Journal of Urology|August 13, 2003
Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormonesWayne J G Hellstrom, James W Overstreet, Albert Yu, et al.
Therapeutic Innovation & Regulatory Science|September 19, 2018
Reference Limits for Outlier Analyses in Randomized Clinical TrialsCharles M Beasley, Brenda Crowe, Mary Nilsson, et al.
Journal of Affective Disorders|June 14, 2002
Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatmentDavid J Brunswick, Jay D Amsterdam, Jan Fawcett, et al.
Journal of Biopharmaceutical Statistics|February 14, 2019
Adaptation of the robust method to large distributions of reference values: program modifications and comparison of alternative computational methodsCharles M Beasley, Brenda Crowe, Mary Nilsson, et al.
European Journal of Pharmacology|October 13, 2004
Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafilR Dustan Sarazan, William J Crumb, Charles M Beasley, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
Journal of Clinical Psychopharmacology|May 16, 2007
All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysisCharles M Beasley, Virginia L Stauffer, Hong Liu-Seifert, et al.
Journal of Clinical Psychopharmacology|November 16, 2007
Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trialsCharles M Beasley, Susan G Ball, Mary E Nilsson, et al.
Pacing and Clinical Electrophysiology : PACE|May 4, 2011
Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditionsCharles M Beasley, Charles Benson, Jessie Q Xia, et al.
The Journal of Clinical Endocrinology and Metabolism|June 7, 2002
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placeboMargaret O Sowell, Nitai Mukhopadhyay, Patrizia Cavazzoni, et al.
Pharmaceutical Research|May 23, 2006
Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysisWilliam J Crumb, Sean Ekins, R Dustan Sarazan, et al.
The Journal of Urology|August 13, 2003
Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormonesWayne J G Hellstrom, James W Overstreet, Albert Yu, et al.
Therapeutic Innovation & Regulatory Science|September 19, 2018
Reference Limits for Outlier Analyses in Randomized Clinical TrialsCharles M Beasley, Brenda Crowe, Mary Nilsson, et al.
Journal of Affective Disorders|June 14, 2002
Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatmentDavid J Brunswick, Jay D Amsterdam, Jan Fawcett, et al.
Journal of Biopharmaceutical Statistics|February 14, 2019
Adaptation of the robust method to large distributions of reference values: program modifications and comparison of alternative computational methodsCharles M Beasley, Brenda Crowe, Mary Nilsson, et al.
European Journal of Pharmacology|October 13, 2004
Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafilR Dustan Sarazan, William J Crumb, Charles M Beasley, et al.
Pageof 3